Partnering with

MOGRIFY

Mogrify is looking to partner with disruptive innovators in the fields of regenerative medicine, ex vivo cell therapy and in vivo reprogramming therapy to develop treatments for indications of high unmet clinical. We are particularly interested in speaking with those with interest in immuno-oncology, ophthalmology as well as other disease areas where these modalities may be of interest. Mogrify is commercializing its technology via a combination of internal therapy development and co-development partnerships, as well as the exploration and generation of novel cell-based and in vivo reprogramming therapies for broad therapeutic application.

Current

PARTNERS

Sangamo Therapeutics

Sangamo Therapeutics

Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients’ lives using gene therapy, cell therapy, and genome engineering.

Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells

MRC Laboratory of Molecular Biology

MRC Laboratory for Molecular Biology

The MRC Laboratory of Molecular Biology (LMB) is a research institute dedicated to the understanding of important biological processes at the levels of atoms, molecules, cells and organisms. In doing so, they provide knowledge needed to solve key problems in human health.

Mogrify enters research collaboration with the MRC Laboratory of Molecular Biology

Duke-NUS Medical School

Duke-NUS Medical School

Duke-NUS Medical School is a research powerhouse and our distinguished scientists are transforming the way we understand, diagnose and treat diseases. Our founder, Assistant Professor, Owen Rackham, and his group at the School focus on what defines human cells and how their phenotype emerges from the complex interplay between the genome, transcriptome and environment. Developing methods that leverage the large volume of gene expression, epigenetic and interaction data that is being generated to develop biological hypotheses about how certain perturbations can influence cell fate.

Monash University

Monash University

The Polo Laboratory, a part of the Monash Biomedicine Discovery Institute at Monash University, focuses on the transcriptional and epigenetic mechanisms that govern cell identity, in particular, pluripotency and the reprogramming of somatic cells into induced pluripotent stem (iPS) cells.

Our

PIPELINE

AREA Sample Acquisition Bioinformatics In vitro PoC In vivo PoC IND Clinical Marketing
Immunotherapy (Oncology) mogrify mogrify mogrify mogrify partner partner
Ophthalmology (Retinal) mogrify mogrify mogrify partner partner
Collaborations (Pulmonary, Metabolic & Others) mogrify mogrify mogrify partner partner partner partner
mogrify Mogrify Progress partner Expect to Partner

Upcoming

Events & Conferences

7 October
-
7 October 2021
Region:
Virtual Conference(s)
Attendee:
Alessadra De Riva, Director of Development, Mogrify
Presentation title:
Presentation date:
Booth:

Advanced Therapies Integrates is dedicated to bringing together the industry leaders to help drive and deliver the full potential advanced therapies and medicinal products (ATMPs).

19 October
-
22 October 2021
Region:
Virtual Conference(s)
Attendee:
Felipe Serrano, Senior Scientist, Mogrify and Duncan Cochrane, Director of Alliances, Mogrify
Presentation title:
Presentation date:
Booth:

The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.

19 October
-
19 October 2021
Region:
Virtual Conference(s)
Host:
Sponsored by Mogrify
Presentation title:
Presentation date:
Booth:

The LSCN will be hosting its 4th annual symposium in collaboration with The Francis Crick Institute. The event will feature keynote speakers Prof Hans Clevers (Hubrecht Institute, The Netherlands) and Prof. Dominique Bonnet, as well as invited speakers and short talks and posters.

25 October
-
28 October 2021
Region:
Virtual Conference(s)
Attendee:
Pierre Louis Joffrin, Corporate Development Executive, Mogrify
Presentation title:
Presentation date:
Booth:

The international BIO-Europe® 2021 gathering will be held digitally on October 25-28, bringing together global biopharma and investment leaders to build partnerships that facilitate innovation and medical breakthroughs.

4 November
-
5 November 2021
Region:
Europe
Attendee:
Stuart Nelis, Senior Bioinformatician, Mogrify
Presentation title:
Presentation date:
Booth:

The 2021 event again brings together a panel of prominent leaders and scientists, sharing new case studies, innovative data and industry outlook.

8 November
-
15 November 2021
Region:
Virtual Conference(s)
Attendee:
Pierre Louis Joffrin, Corporate Development Executive, Mogrify
Presentation title:
Presentation date:
Booth:

LSX’s Investival Showcase connects life science corporates to global capital and partners in an international showcase of early, growth stage and public life science and health technology companies across Europe and beyond.

22 November
-
23 November 2021
Region:
Europe
Attendee:
Geraint Parfitt, Manager of Ophthalmology, Mogrify
Presentation title:
Presentation date:
Booth:

The 4th Annual Ophthalmic Drugs Conference taking place in person on the 22nd-23rd of November 2021, in London.

28 November
-
1 December 2021
Region:
Europe
Attendee:
Pepe Ballester, Senior Scientist, Mogrify
Presentation title:
Presentation date:
Booth:

The British Society for Immunology Congress 2021, the annual flagship event, will take place from 28 November to 1 December 2021 in Edinburgh, UK.

11 December
-
14 December 2021
Region:
US
Attendee:
David Matthews, Director of R&D, Mogrify and Chris Oliphant, Manager of Immunology, Mogrify
Presentation title:
Presentation date:
Booth:

The American Society of Hematology (ASH) Annual Meeting & Exposition is the annual premier event in malignant and non-malignant hematology.